Mode
Text Size
Log in / Sign up
Phase 2 N=61 Randomized Treatment

Multifaceted Treatment of Catheter-related Urinary Tract Infection

Spinal Cord Injury · Neurogenic Bladder · Urinary Tract Infection

Enrolled (actual)
61
Serious AEs
0.0%
Results posted
Nov 2014
Primary outcome: Primary: The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as Resolution of Clinical Manifestations of Infection Plus Lack of Growth of the Original Infect — 28; 27 participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Shortened course of antibiotic therapy (Other); Standard Therapy (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
US Department of Veterans Affairs
Primary completion
Dec 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
The Primary Efficacy Outcome of the Study is Response to Treatment Which Will be Assessed at the End of Therapy. Successful Response to Treatment is Defined as Resolution of Clinical Manifestations of Infection Plus Lack of Growth of the Original Infect
28; 27
SECONDARY
The Secondary Efficacy Outcome is Recurrence of UTI up to 180 Days After the End of Therapy
9; 3

Summary

The specific objective of this clinical trial is to demonstrate that a multifaceted approach for treatment for catheter-related urinary tract infection (UTI) in patients with spinal cord injury is effective and feasible. We plan to test the following hypothesis: a multifaceted treatment approach that consists of immediate removal of the indwelling bladder catheter, selecting antibiotics based on the finding from a urine culture that is obtained through the newly inserted catheter, and a 5-day course of systemic antibiotics will effectively treat catheter-related infection that is limited to the lower urinary tract of patients with spinal cord injury.

Eligibility Criteria

Inclusion Criteria

  • Adult patients with SCI who are hospitalized at the Michael E. Debakey VA Medical Center and suffer from lower UTI associate with an indwelling transurethral or suprapubic bladder catheter will be enrolled in the study

Exclusion Criteria

  • Exclusion criteria will include septicemia, chronic antimicrobial therapy and inability, or unwillingness to give informed consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00732238). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search